Home > PJ > News / Daily News

Return to PJ Online Home Page

The Pharmaceutical Journal Vol 267 No 7164 p313-316
8 September 2001

This article
Reprint
Photocopy


News summary


Department rejects claims that MMR is ineffective

Claims made by a private clinic that 50 per cent of children who receive measles, mumps and rubella (MMR) vaccine are inadequately protected against measles and mumps have been rejected by the Department of Health.

Tests for antibody levels were performed by the Direct Health 2000 clinic in Eltham, London, on 50 children who had had the first of two MMR vaccinations. About half were found to have “good” immunity to rubella but “zero or very low” protection against measles and mumps.

Dismissing Direct Health’s claim, the Department of Health says that inferring that MMR is ineffective from these results is misleading. “These tests were carried out by a clinic which has a vested interest in selling single vaccines and the results have not been published or validated by other researchers. They should be treated with extreme caution,” it says.

The department adds that previous research has shown that up to 10 per cent of children might not have immunity to measles and mumps, and less than 5 per cent to rubella after the first MMR injection. “The second dose is designed to protect children who do not respond to the first dose or who have lower levels of immunity.”

Dr Paul Shattock, director of the autism research unit at the University of Sunderland, expressed his surprise at the clinic’s findings. “I have read all the published papers on efficacy [of MMR vaccine] and have never had any reason to doubt them. Indeed, I was beginning to wonder whether the second shot was needed at all.” He went on to say: “I believe it is appropriate to investigate the claims experimentally. It is not appropriate for a group of immunologists and public health officials to dismiss these allegations out of hand.”

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal